3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
pembrolizumab
4
Drug Therapy
3
Temozolomide
2
Radiation
2
Paclitaxel
2
Nivolumab
2
Cisplatin
2
Bevacizumab
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
selinexor
1
rovalpituzumab tesirine
1
regorafenib
1
pazopanib
1
niraparib
1
imetelstat
1
fludarabine
1
erythromycin propionate-N-acetylcysteinate
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dostarlimab
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
bemcentinib
1
aflibercept
1
WP1066
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
bemcentinib
×
Dermatologic
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts